Q1 EPS Forecast for Puma Biotechnology Lowered by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Zacks Research lowered their Q1 2027 EPS estimates for Puma Biotechnology in a report issued on Friday, January 16th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of $0.08 for the quarter, down from their prior estimate of $0.09. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q3 2027 earnings at $0.07 EPS.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 6th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.12. Puma Biotechnology had a net margin of 17.45% and a return on equity of 36.17%. The firm had revenue of $54.48 million for the quarter, compared to analyst estimates of $51.00 million.

PBYI has been the subject of several other reports. Weiss Ratings cut Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Puma Biotechnology Trading Up 3.6%

Shares of PBYI stock opened at $6.60 on Monday. The stock has a market cap of $332.57 million, a P/E ratio of 8.92 and a beta of 1.19. Puma Biotechnology has a 1 year low of $2.58 and a 1 year high of $6.66. The stock has a 50 day simple moving average of $5.62 and a 200 day simple moving average of $4.95.

Institutional Trading of Puma Biotechnology

A number of hedge funds have recently added to or reduced their stakes in PBYI. CWM LLC grew its stake in shares of Puma Biotechnology by 214.1% in the second quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 6,450 shares during the last quarter. Cerity Partners LLC acquired a new position in Puma Biotechnology during the 2nd quarter worth about $36,000. BNP Paribas Financial Markets grew its position in shares of Puma Biotechnology by 39.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 2,290 shares during the last quarter. Savant Capital LLC bought a new stake in shares of Puma Biotechnology in the 2nd quarter valued at about $44,000. Finally, Ethic Inc. acquired a new stake in shares of Puma Biotechnology in the second quarter valued at about $51,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Insider Buying and Selling at Puma Biotechnology

In other Puma Biotechnology news, Director Michael Patrick Miller sold 20,000 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $4.86, for a total transaction of $97,200.00. Following the completion of the transaction, the director owned 54,000 shares of the company’s stock, valued at approximately $262,440. The trade was a 27.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Alan H. Auerbach sold 18,012 shares of the stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $5.88, for a total transaction of $105,910.56. Following the completion of the transaction, the chief executive officer directly owned 7,145,951 shares of the company’s stock, valued at $42,018,191.88. This trade represents a 0.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 63,937 shares of company stock worth $354,713 over the last 90 days. Insiders own 23.30% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.